{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T21:04:28Z","timestamp":1754600668541,"version":"3.41.2"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T00:00:00Z","timestamp":1685404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>We report a case of autoimmune bullous disease (AIBD) with IgG and IgM autoantibodies against epidermal basement membrane zone (BMZ), which showed recurrence of mucocutaneous lesions after coronavirus disease 2019 (COVID-19) mRNA vaccination. A 20-year-old Japanese woman with a 4-year history of epidermolysis bullosa acquisita (EBA) presented to our clinic. She noticed fever and rash on the same day and visited at our hospital 2 days later. Physical examination revealed blisters, erosions and erythema on the face, shoulder, back, upper arms, and lower lip. A skin biopsy from the forehead showed subepidermal blister. Direct immunofluorescence showed linear depositions of IgG, IgM, and C3c in the epidermal BMZ. By indirect immunofluorescence of 1M NaCl-split normal human skin, circulating IgG autoantibodies were bound to the dermal side of the split at 1:40 serum dilution, and circulating IgM antibodies were bound to the epidermal side of the spilt. After the increase of prednisolone dose to 15 mg\/day, the mucocutaneous lesions resolved in a week. The present case is the first case of possible EBA with IgG and IgM anti-BMZ antibodies, in which the mucocutaneous lesions were recurred after COVID-19 mRNA vaccination. Clinicians should be aware that bullous pemphigoid-like AIBDs, including EBA and IgM pemphigoid, might be developed after COVID-19 mRNA vaccination.<\/jats:p>","DOI":"10.3389\/fmed.2023.1093827","type":"journal-article","created":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T10:30:40Z","timestamp":1685615440000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Case report: A case of epidermolysis bullosa acquisita with IgG and IgM anti-basement membrane zone antibodies relapsed after COVID-19 mRNA vaccination"],"prefix":"10.3389","volume":"10","author":[{"given":"Satoko","family":"Minakawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Matsuzaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shogo","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chihiro","family":"Sagara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eijiro","family":"Akasaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Koga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norito","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Sawamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1111\/bjd.14692","article-title":"Summary of results of serological tests and diagnoses for 4774 cases of various autoimmune bullous diseases consulted to Kurume University","volume":"175","author":"Hashimoto","year":"2016","journal-title":"Br J Dermatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1080\/1744666X.2016.1221343","article-title":"Clinical features and diagnosis of epidermolysis bullosa acquisita","volume":"13","author":"Vorobyev","year":"2017","journal-title":"Expert Rev Clin Immunol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"362","DOI":"10.3389\/fmed.2018.00362","article-title":"Epidermolysis bullosa acquisita: the 2019 update","volume":"5","author":"Koga","year":"2018","journal-title":"Front Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1016\/j.jaad.2021.04.061","article-title":"Association between vaccination and autoimmune bullous diseases: a systematic review","volume":"86","author":"Kasperkiewicz","year":"2022","journal-title":"J Am Acad Dermatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.annder.2021.07.008","article-title":"Bullous pemphigoid induced by the AstraZeneca COVID-19 vaccine","volume":"149","author":"Agharbi","year":"2022","journal-title":"Ann Dermatol Venereol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.jaci.2021.06.026","article-title":"Subepidermal blistering eruptions, including bullous pemphigoid, following COVID-19 vaccination","volume":"148","author":"Tomayko","year":"2021","journal-title":"J Allergy Clin Immunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jaad.2021.09.002","article-title":"Clinical and pathologic correlation of cutaneous COVID-19 vaccine reactions including V-REPP: a registry-based study","volume":"86","author":"McMahon","year":"2022","journal-title":"J Am Acad Dermatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1111\/1346-8138.16260","article-title":"Super-resolution imaging detects BP180 autoantigen in immunoglobulin M pemphigoid","volume":"49","author":"Hirano","year":"2022","journal-title":"Dermatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1111\/j.1600-0560.1994.tb00261.x","article-title":"Occurrence of positive immunofluore scence in the dermo-epidermal junction of sun-exposed skin of normal adults","volume":"21","author":"Leibold","year":"1994","journal-title":"J Cutan Pathol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"899526","DOI":"10.3389\/fimmu.2022.899526","article-title":"Autoimmune skin disease exacerbations following COVID-19 vaccination","volume":"13","author":"Sprow","year":"2022","journal-title":"Front Immunol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1111\/bjd.20890","article-title":"Bullous pemphigoid after SARS-CoV-2 vaccination: spike-protein-directed immunofluorescence confocal microscopy and T-cell-receptor studies","volume":"186","author":"Gambichler","year":"2022","journal-title":"Br J Dermatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/j.jid.2017.12.035","article-title":"Vancomycin mediates IgA autoreactivity in drug-induced linear IgA bullous dermatosis","volume":"138","author":"Yamagami","year":"2018","journal-title":"J Invest Dermatol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.14924\/dermatol.131.2595","article-title":"Clinical analyses of 22 cases with cutaneous reactions after COVID-19 vaccination","volume":"131","author":"Ishikawa","year":"2021","journal-title":"Jpn J Dermatol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S0190-9622(81)70076-8","article-title":"Epidermolysis bullosa acquisita: a heterogeneous disease","volume":"5","author":"Palestine","year":"1981","journal-title":"J Am Acad Dermatol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"812029","DOI":"10.1155\/2013\/812029","article-title":"Clinical presentation, pathogenesis, diagnosis, and treatment of epidermolysis bullosa acquisita","volume":"2013","author":"Ludwig","year":"2013","journal-title":"ISRN Dermatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/S0140-6736(12)61140-4","article-title":"Pemphigoid diseases","volume":"381","author":"Schmidt","year":"2013","journal-title":"Lancet."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1111\/jdv.15679","article-title":"Review of autoimmune blistering diseases: the pemphigoid diseases","volume":"33","author":"Daniel","year":"2019","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/j.1346-8138.2009.00799.x","article-title":"Epidermolysis bullosa acquisita: what's new?","volume":"37","author":"Ishii","year":"2010","journal-title":"J Dermatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1001\/archderm.1957.01550160015002","article-title":"Benign pemphigold; a report of seven cases with chronic, scarring, herpetiform plaques about the head and neck","volume":"75","author":"Brunsting","year":"1957","journal-title":"AMA Arch Dermatol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e90","DOI":"10.1097\/DAD.0000000000000829","article-title":"Epidermolysis bullosa acquisita (Brunsting-Perry pemphigoid variant) localized to the face and diagnosed with antigen identification using skin deficient in type VII collagen","volume":"39","author":"Asfour","year":"2017","journal-title":"Am J Dermatopathol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1159\/000485570","article-title":"Brunsting-Perry type pemphigoid causing secondary cicatricial alopecia in 2 patients","volume":"4","author":"Reis Gavazzoni Dias","year":"2018","journal-title":"Skin Appendage Disord."},{"key":"B22","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/cup.14177","article-title":"Cicatricial pemphigoid Brunsting-Perry variant masquerading as neutrophil-mediated cicatricial alopecia","volume":"49","author":"Rahbar","year":"2022","journal-title":"J Cutan Pathol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e224","DOI":"10.1111\/j.1468-3083.2012.04617.x","article-title":"Serum levels of anti-type VII collagen antibodies detected by enzyme-linked immunosorbent assay in patients with epidermolysis bullosa acquisita are correlated with the severity of skin lesions","volume":"27","author":"Kim","year":"2013","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e01136","DOI":"10.1002\/cti2.1136","article-title":"Detection of IgM and IgG antibodies in patients with coronavirus disease 2019","volume":"9","author":"Hou","year":"2020","journal-title":"Clin Transl Immunol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e302","DOI":"10.1111\/jdv.16525","article-title":"Expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic","volume":"34","author":"Kasperkiewicz","year":"2020","journal-title":"J Eur Acad Dermatol Venereol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1093827\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T10:30:43Z","timestamp":1685615443000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1093827\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,30]]},"references-count":25,"alternative-id":["10.3389\/fmed.2023.1093827"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1093827","relation":{},"ISSN":["2296-858X"],"issn-type":[{"type":"electronic","value":"2296-858X"}],"subject":[],"published":{"date-parts":[[2023,5,30]]},"article-number":"1093827"}}